Attovia Therapeutics stock
ATTONASDAQAttovia Therapeutics, Inc., HealthcareISIN US04987L1026
46Score 46 out of 100, Weak
Price and trend
76 / 100
Price history
−28% since 2026The chart shows daily closing prices since 5 Aug 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 38% below its 52-week high. Largest decline since 5 Aug 2026: 46% (September 2026 to October 2026).
Chart figures for advanced users
- SMA 50$17.71
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.81
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.73
- The lowest closing price of the last twelve months.
- Resistance$25.55
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Attovia Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $722.72M, is number 211 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 46 out of 100 (Weak): rank 441 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $152.27M, financial debt $5.26M.Stability 69
Weaknesses
- Loss-makingLoss of $60.63M over the last 12 months.Fundamentals 10
- Negative free cash flowFree cash flow −$61.51M over the last 12 months.Fundamentals 10
Its standout strengths are momentum and technical analysis, while profitability and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
The share count in the financial statements does not match the market value (factor 6.4). Per-share figures such as the P/E and the fair value are therefore treated as not measured until the data match.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue turned from negative at the start of the period to positive ($1.35M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 40%, operating −4975%, net −4491%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low; no interest coverage is reported.
Earnings
- Next earnings
- 8 Feb 2027in 88 days
- Last reported
- 9 Nov 2026EPS reported −$0.76 (expected −$0.56)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$4.060.0%
- Revenue
- $450K0.0%
- Earnings per share
- −$2.380.0%
- Revenue
- $1.35M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $466,658 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Not counted: 6 purchases under a fixed plan (compensation, savings plan or a pre-arranged Rule 10b5-1 trading plan).
- Walsh Colin, Goldman Sachs Group IncPlan purchase
6 Aug 2026, Board
- Shares
- 500,000
- Price
- $17.00
- Value
- $8.5M
- venBio Global Strategic Fund IV, L.P.Plan purchase
6 Aug 2026, Major holder
- Shares
- 382,352
- Price
- $17.00
- Value
- $6.5M
- Redmile Group, LLCPlan purchase
6 Aug 2026, Major holder
- Shares
- 600,000
- Price
- $17.00
- Value
- $10.2M
Show 4 more
- SanofiPlan purchase
6 Aug 2026, Major holder
- Shares
- 300,000
- Price
- $17.00
- Value
- $5.1M
- Frazier Life Sciences XI, L.P.Plan purchase
6 Aug 2026, Major holder
- Shares
- 588,235
- Price
- $17.00
- Value
- $10M
- Walsh Colin, Goldman Sachs Group IncPurchase
5 Aug 2026, Board
- Shares
- 85,000
- Price
- $21.00
- Value
- $1.79M
- Walsh Colin, Goldman Sachs Group IncSale
5 Aug 2026, Board
- Shares
- 105,807
- Price
- $21.28
- Value
- $2.25M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Attovia Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 46
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Aura BiosciencesAURA $789.19M42
- ArdelyxARDX $786.8M34
- Prime MedicinePRME $779.92M41
- Arbutus BiopharmaABUS $768.65M65
- Janux TherapeuticsJANX $758.06M33
- DBV TechnologiesDBV.PA $744.68M41
- OmniAbOABI $743.89M54
- GubraGUBRA.CO $726.32M41
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.